April 2026
1. ROSS D, Split M, Kunicki Z, Keszycki R, et al
   Neuropsychiatric Symptoms in Patients With Pathologically Confirmed Comorbid Alzheimer Disease and Frontotemporal Lobar Degeneration.
   Neurology. 2026;106:e214750.
   

   >> Share

   
   
2. CLARK AL, Asimakopoulos G, Valocchi E, Chanfreau-Coffinier C, et al
   Individual-Level Factors Associated With 10-Year Incidence of Alzheimer Disease and Related Dementias in the VA Million Veteran Program.
   Neurology. 2026;106:e214748.
   

   >> Share

   
   
3. LORENZINI L, Tranfa M, Kate MT, Braber AD, et al
   CSF Proteomic Profiles Associated With White Matter Integrity in Cognitively Normal Older Adults With and Without Amyloid Pathology.
   Neurology. 2026;106:e214675.
   

   >> Share

   
   March 2026
4. VILLAIN N
   Reader Response: Alzheimer Disease Is a Specific Disorder Defined by Neuropathology Detectable During Life.
   Neurology. 2026;106:e210188.
   

   >> Share

   
   
5. VILLAIN N, Hanseeuw BJ, Planche V, Paretsky MS, et al
   Author Response: The Great Debate in Diagnosing Alzheimer Disease: More Than Just a beta Test.
   Neurology. 2026;106:e210240.
   

   >> Share

   
   
6. GANESH A, Galetta SL
   Editors' Note: Diagnostic and Prognostic Implications of Biomarker-Based Criteria for Alzheimer Disease.
   Neurology. 2026;106:e214259.
   

   >> Share

   
   
7. BIEGER A, Brum WS, Borelli WV, Ferrari-Souza JP, et al
   Reader Response: The Great Debate in Diagnosing Alzheimer Disease: More Than Just a beta Test.
   Neurology. 2026;106:e210159.
   

   >> Share

   
   
8. HALL BJ, Aumont E, Hosseini SA, Fernandez Arias J, et al
   Association of Cortical Free Water With Brain Tau Tangle Load in the Alzheimer Disease Continuum.
   Neurology. 2026;106:e214606.
   

   >> Share

   
   
9. NELSON PT, Jicha GA
   Tau Biomarker-Based Diagnosis of Alzheimer Disease and the Anti-Abeta Therapeutic Window: Is There Overlap?
   Neurology. 2026;106:e214696.
   

   >> Share

   
   
10. VRILLON A, Spina S, Mejia-Perez J, Lamore T, et al
    Association of [(18)F]Flortaucipir-PET and Plasma p-Tau217 With Tau Neuropathology in Alzheimer Disease and Other Neurodegenerative Disorders.
    Neurology. 2026;106:e214576.
    

    >> Share

    
    
11. ZAMMIT AR, Yu L, Poole VN, Kapasi A, et al
    Associations of Lifetime Cognitive Enrichment With Incident Alzheimer Disease Dementia, Cognitive Aging, and Cognitive Resilience.
    Neurology. 2026;106:e214677.
    

    >> Share

    
    February 2026
12. KIVISAKK P, Fatima H, Wu CY, Padmanabhan N, et al
    Postmortem Associations Between Alzheimer Disease Pathology and Plasma pTau217, GFAP, and NfL in AD and AD-Related Dementias.
    Neurology. 2026;106:e214351.
    

    >> Share

    
    
13. IRWIN DJ
    Blood-Based Biomarkers and the Complexity of Neuropathologic Substrates of Alzheimer Disease and Related Disorders.
    Neurology. 2026;106:e214504.
    

    >> Share

    
    
14. RANI N, Moghekar A, Callow DD, Alm KH, et al
    Association Between Longitudinal Rate of Change in CSF Biomarkers and Subsequent Tau PET Burden in Early Braak Stages.
    Neurology. 2026;106:e214620.
    

    >> Share

    
    January 2026
15. DU Y, Borne Y, Samuelsson J, Glans I, et al
    High- and Low-Fat Dairy Consumption and Long-Term Risk of Dementia: Evidence From a 25-Year Prospective Cohort Study.
    Neurology. 2026;106:e214343.
    

    >> Share

    
    
16. ROVETA F, Pizzini FB, Natale V, Scheffler M, et al
    Utility of the Amygdalar Atrophy Scale to Identify Patients With Limbic-Predominant Age-Related TDP-43 Encephalopathy in a Memory Clinic.
    Neurology. 2026;106:e214477.
    

    >> Share

    
    
17. GASPARINI F, Valletta M, Vetrano DL, Beridze G, et al
    Kidney Function, Alzheimer Disease Blood Biomarkers, and Dementia Risk in Community-Dwelling Older Adults.
    Neurology. 2026;106:e214446.
    

    >> Share

    
    
18. FERREIRA PCL, Bellaver B, Povala G, Bauer-Negrini G, et al
    Evaluating Plasma p-tau217 as an Endpoint for Alzheimer Disease Clinical Trials.
    Neurology. 2026;106:e214441.
    

    >> Share

    
    
19. BENDER AC, Berezuk C, Pellerin KR, You JC, et al
    Association of Sleep Spindle Activity With Cognitive Decline in Early Clinical Stages of Alzheimer Disease.
    Neurology. 2026;106:e214459.
    

    >> Share

    
    
20. JUNG YH, Cho J, Lee SY, Seo HE, et al
    Impact of Cerebral Microbleeds on Tau-Associated Cognitive and Structural Decline.
    Neurology. 2026;106:e214453.
    

    >> Share

    
    December 2025
21. COUGHLIN DG, Jain L, Khrestian M, Bozoki AC, et al
    CSF alpha-Synuclein Seed Amplification Assays and Alzheimer Disease Biomarkers in Dementia With Lewy Bodies: Presentation and Progression.
    Neurology. 2025;105:e214346.
    

    >> Share

    
    
22. FILIPPI M, Cecchetti G
    Choroid Plexus Morphology in Alzheimer Disease: Bridging Pathology and Cognition.
    Neurology. 2025;105:e214017.
    

    >> Share

    
    
23. LIN M, Zeng Q, Zhong S, Nie S, et al
    Association Between Choroid Plexus Morphological Alterations, Alzheimer Pathologies, and Cognitive Impairment: A Longitudinal Study.
    Neurology. 2025;105:e213953.
    

    >> Share

    
    
24. KRELL-ROESCH J, Syrjanen JA, Hansen AL, Vemuri P, et al
    Physical and Cognitive Activities and Trajectories of AD Neuroimaging Biomarkers: Longitudinal Analysis in the Mayo Clinic Study of Aging.
    Neurology. 2025;105:e214405.
    

    >> Share

    
    November 2025
25. BENITO-LEON J, Benito-Rodriguez CM
    Essential Tremor Dementia: Alzheimer Disease in Disguise?
    Neurology. 2025;105:e214420.
    

    >> Share

    
    
26. RAMOS-CEJUDO J, Beiser AS, Lu S, Tanner JA, et al
    Association of Platelet Aggregation With Markers of Alzheimer Disease Pathology in Middle-Aged Participants of the Framingham Heart Study.
    Neurology. 2025;105:e214314.
    

    >> Share

    
    
27. PRODAN CI, Dale GL
    Platelets and Alzheimer Disease: A Link Worth Exploring.
    Neurology. 2025;105:e214438.
    

    >> Share

    
    
28. ROSENAU C, Neuffer J, Kohler S, Helmer C, et al
    Updated LIfestyle for BRAin health (LIBRA2) Score, Genetics, and Risk of Alzheimer Disease, Vascular Dementia, and Stroke in Older Adults.
    Neurology. 2025;105:e214312.
    

    >> Share

    
    
29. MOURTZI N, Charisis S, Ntanasi E, Hatzimanolis A, et al
    Longitudinal Association of a Polygenic Risk Score for Plasma T-Tau With Incident Alzheimer Dementia and Mild Cognitive Impairment.
    Neurology. 2025;105:e213904.
    

    >> Share

    
    
30. EDWARDS NC, Lao P, Alshikho MJ, Mazen J, et al
    Alzheimer Disease, Vascular Disease, and Blood-Brain Barrier Permeability Biomarkers in Middle-Aged Adults.
    Neurology. 2025;105:e214220.
    

    >> Share

    
    
31. ONG JJH, Leow YJ, Qiu B, Tanoto P, et al
    Association of Enlarged Perivascular Spaces With Early Serum and Neuroimaging Biomarkers of Alzheimer Disease Pathology.
    Neurology. 2025;105:e214339.
    

    >> Share

    
    
32. LOPEZ-MARTOS D, Suarez-Calvet M, Mila-Aloma M, Gispert JD, et al
    Longitudinal Associations of Multimodal Core 1 Alzheimer Disease Biomarkers With Cognition in Aging and Preclinical Alzheimer Disease.
    Neurology. 2025;105:e214308.
    

    >> Share

    
    October 2025
33. TRUDEL L, Therriault J, Macedo AC, Servaes S, et al
    Implication for Clinical Trials From Longitudinal Tau-PET Accumulation Across Biological Alzheimer Disease Stages.
    Neurology. 2025;105:e214111.
    

    >> Share

    
    
34. ESTELLER-GAUXAX D, Perez Millan A, Sarto J, Puey R, et al
    alpha-Synuclein Seed Amplifications Assay in a Cohort With Cognitive Impairment: Performance and Interactions With CSF and Plasma Biomarkers.
    Neurology. 2025;105:e214040.
    

    >> Share

    
    
35. BOCCALINI C, Mathoux G, Hristovska I, Ribaldi F, et al
    Visual Classification of Tau-PET Detects 4 Subtypes With Different Long-Term Outcomes.
    Neurology. 2025;105:e213950.
    

    >> Share

    
    September 2025
36. OVEISGHARAN S, Yu L, Yang J, Agrawal S, et al
    Cortical Gray Matter Proteins Associated With Cerebral Amyloid Angiopathy in Community-Dwelling Older Adults: An Autopsy Study.
    Neurology. 2025;105:e214024.
    

    >> Share

    
    
37. ONG JJH, Leow YJ, Qiu B, Tanato P, et al
    Association of Enlarged Perivascular Spaces With Early Serum and Neuroimaging Biomarkers of Alzheimer Disease Pathology.
    Neurology. 2025;105:e213836.
    

    >> Share

    
    
38. YIM S, Park S, Lim K, Kang H, et al
    Integrating MRI Volume and Plasma p-Tau217 for Amyloid Risk Stratification in Early-Stage Alzheimer Disease.
    Neurology. 2025;105:e213954.
    

    >> Share

    
    
39. SCHAFFERT J, Iyengar N, Magill R, LoBue C, et al
    Clinical and Neuropsychological Profiles in People With Chronic Traumatic Encephalopathy Neuropathologic Change: Matched Case-Series Study.
    Neurology. 2025;105:e214012.
    

    >> Share

    
    
40. WANG X, Ye T, Zhou W, Zhang J, et al
    Association of Distinct Initial beta-Amyloid Levels With Tau Pathology Expansion Beyond the Entorhinal Cortex.
    Neurology. 2025;105:e214041.
    

    >> Share

    
    
41. WANG L, Xu H, Simons RL, Beach SRH, et al
    Associations of Longitudinal Changes in Blood Biomarkers of Dementia With the Proportion of Genetically Inferred African Ancestry.
    Neurology. 2025;105:e213976.
    

    >> Share

    
    
42. RAJAN KB, Evans DA
    Author Response: Statin Initiation and Risk of Incident Alzheimer Disease and Cognitive Decline in Genetically Susceptible Older Adults.
    Neurology. 2025;105:e210185.
    

    >> Share

    
    
43. LEWIS A, Galetta SL
    Editors' Note: Statin Initiation and Risk of Incident Alzheimer Disease and Cognitive Decline in Genetically Susceptible Older Adults.
    Neurology. 2025;105:e213696.
    

    >> Share

    
    
44. KAWADA T
    Reader Response: Statin Initiation and Risk of Incident Alzheimer Disease and Cognitive Decline in Genetically Susceptible Older Adults.
    Neurology. 2025;105:e209998.
    

    >> Share

    
    
45. KAPASI A, James BD, Yu L, Sood A, et al
    Mixed Pathologies and Cognitive Outcomes in Persons Considered for Anti-Amyloid Treatment Eligibility Assessment: A Community-Based Study.
    Neurology. 2025;105:e214004.
    

    >> Share

    
    
46. PETERSEN RC
    Alzheimer Disease Treatments and Co-Pathologies: But At What Age?
    Neurology. 2025;105:e214061.
    

    >> Share

    
    August 2025
47. FUKUYAMA H
    Cerebral Small Vessel Disease and Alzheimer Disease: The Vascular Link Through MRI Diffusion.
    Neurology. 2025;105:e214052.
    

    >> Share

    
    
48. PALPATZIS E, Akinci M, Garcia-Prat M, Blennow K, et al
    Grief and Economic Stressors by Sex, Gender, and Education: Associations With Alzheimer Disease-Related Outcomes.
    Neurology. 2025;105:e214053.
    

    >> Share

    
    July 2025
49. TRANFA M, Oliveira TG
    Scratching Beneath the Cortex: Superficial White Matter and Alzheimer Disease.
    Neurology. 2025;105:e213830.
    

    >> Share

    
    
50. WANG S, Zhang F, Zeng Q, Hong H, et al
    Association of Superficial White Matter Microstructure With Cortical Pathology Deposition Across Early Stages of the AD Continuum.
    Neurology. 2025;105:e213666.
    

    >> Share

    
    
51. BARNARD L, Botha H, Corriveau-Lecavalier N, Graff-Radford J, et al
    An FDG-PET-Based Machine Learning Framework to Support Neurologic Decision-Making in Alzheimer Disease and Related Disorders.
    Neurology. 2025;105:e213831.
    

    >> Share

    
    
52. VANDERLIP CR, Stark CEL
    Time Course and Severity of Cognitive Changes as a Function of Abeta Positivity and APOE Genotype in Alzheimer Disease.
    Neurology. 2025;105:e213853.
    

    >> Share

    
    
53. ZIMMERMAN SC, Choi M, Jiang C, Ferguson EL, et al
    Statin Initiation and Dementia Incidence in a Large Health Care System From 1997 to 2020: A Target Trial Emulation Study.
    Neurology. 2025;105:e213855.
    

    >> Share

    
    
54. GOGNIAT MA, Khan OA, Ratangee B, Bolton CJ, et al
    Cross-Sectional and Longitudinal Associations of Neighborhood Disadvantage With Fluid Biomarkers of Neuroinflammation and Neurodegeneration.
    Neurology. 2025;105:e213770.
    

    >> Share

    
    
55. SELMA-GONZALEZ J, Rubio-Guerra S, Garcia-Castro J, Vera-Campuzano E, et al
    Association of Plasma Phosphorylated Tau 217 With Clinical Deterioration Across Alzheimer Disease Stages.
    Neurology. 2025;105:e213769.
    

    >> Share

    
    June 2025
56. DUBBELMAN MA, Liu A, Donohue MC, Langford O, et al
    Changes in Daily Functioning in Association With Tau and Amyloid Among Unimpaired Older Adults With and Without Elevated Amyloid.
    Neurology. 2025;104:e213775.
    

    >> Share

    
    
57. CHARISIS S, Lu S, Melgarejo JD, Satizabal CL, et al
    Association of Blood Lipoprotein Levels With Incident Alzheimer Disease in Community-Dwelling Individuals: The Framingham Heart Study.
    Neurology. 2025;104:e213715.
    

    >> Share

    
    
58. SHRESTHA S, Zhu X, Griswold ME, Palta P, et al
    Olfaction and Plasma Biomarkers of Alzheimer Disease and Neurodegeneration in the Atherosclerosis Risk in Communities Study.
    Neurology. 2025;104:e213706.
    

    >> Share

    
    
59. GONZALEZ-ORTIZ F, Kirsebom BE, Yakoub Y, Gundersen JK, et al
    Associations Between Changes in Levels of Phosphorylated Tau and Severity of Cognitive Impairment in Early Alzheimer Disease.
    Neurology. 2025;104:e213676.
    

    >> Share

    
    
60. MENDES AJ, Ribaldi F, Pievani M, Boccalini C, et al
    Validating the Amyloid Cascade Through the Revised Criteria of Alzheimer's Association Workgroup 2024 for Alzheimer Disease.
    Neurology. 2025;104:e213675.
    

    >> Share

    
    May 2025
61. LEE JY, Han K, Kim J, Lim JS, et al
    Association Between Metabolic Syndrome and Young-Onset Dementia: A Nationwide Population-Based Study.
    Neurology. 2025;104:e213599.
    

    >> Share

    
    
62. BADER I, Groot C, Van Der Flier WM, Pijnenburg YAL, et al
    Survival Differences Between Individuals With Typical and Atypical Phenotypes of Alzheimer Disease.
    Neurology. 2025;104:e213603.
    

    >> Share

    
    
63. JUSTO AFO, Paradela R, Gomes Goncalves N, Ribeiro Paes V, et al
    Association Between Alcohol Consumption, Cognitive Abilities, and Neuropathologic Changes: A Population-Based Autopsy Study.
    Neurology. 2025;104:e213555.
    

    >> Share

    
    
64. COLLIJ LE, Mastenbroek SE
    Your Alzheimer Risk: How Your Sex and Your Affected Parent's Sex Independently Shape the Odds.
    Neurology. 2025;104:e213622.
    

    >> Share

    
    
65. OURRY V, Fajardo-Valdez A, Soucy JP, Poirier J, et al
    Amyloid and Tau Pathology in Cognitively Unimpaired Individuals With a Parental History of Alzheimer Disease: Role of Sex and Parent's Sex.
    Neurology. 2025;104:e213507.
    

    >> Share

    
    
66. THOMAS KR, Edmonds EC
    Objective Criteria for Subtle Cognitive Decline in Aging and Preclinical Alzheimer Disease: A Systematic Review.
    Neurology. 2025;104:e213536.
    

    >> Share

    
    
67. STOCKER H, Beyer L, Trares K, Stevenson-Hoare J, et al
    Association of Nonmodifiable Risk Factors With Alzheimer Disease Blood Biomarkers in Community-Dwelling Adults in the ESTHER Study.
    Neurology. 2025;104:e213500.
    

    >> Share

    
    April 2025
68. JEONG SY, Suh CH, Lim JS, Shim WH, et al
    Incidence of Amyloid-Related Imaging Abnormalities in Phase III Clinical Trials of Anti-Amyloid-beta Immunotherapy: An Updated Meta-Analysis.
    Neurology. 2025;104:e213483.
    

    >> Share

    
    
69. SHUMAN PARETSKY M
    The Impact of Social Vulnerability on Cognitive Decline and Incident Alzheimer Disease.
    Neurology. 2025;104:e213582.
    

    >> Share

    
    
70. DESAI P, Bond J, Dhana A, Ng TKS, et al
    The Social Vulnerability Index and Incidence of Alzheimer Disease in a Population-Based Sample of Older Adults.
    Neurology. 2025;104:e213464.
    

    >> Share

    
    
71. NALLAPU BT, Petersen KK, Qian T, Demirsoy I, et al
    A Machine Learning Approach to Predict Cognitive Decline in Alzheimer Disease Clinical Trials.
    Neurology. 2025;104:e213490.
    

    >> Share

    
    
72. PALPATZIS E, Akinci M, Garcia-Prat M, Blennow K, et al
    Grief and Economic Stressors by Sex, Gender, and Education: Associations With Alzheimer Disease-Related Outcomes.
    Neurology. 2025;104:e213377.
    

    >> Share

    
    
73. WILLIAMS JP, Babulal GM
    Hakuna Matata: How Interventions for Stressful Life Events and Other Social Determinants of Health Intersect With Alzheimer Disease.
    Neurology. 2025;104:e213455.
    

    >> Share

    
    
74. SANCHEZ E, Coughlan GT, Wilkinson T, Ramirez J, et al
    Association of Plasma Biomarkers With Longitudinal Atrophy and Microvascular Burden on MRI Across Neurodegenerative and Cerebrovascular Diseases.
    Neurology. 2025;104:e213438.
    

    >> Share

    
    March 2025
75. HOLPER S, Loveland PM, Churilov L, Italiano D, et al
    Author Response: Blood Astrocyte Biomarkers in Alzheimer Disease: A Systematic Review and Meta-Analysis.
    Neurology. 2025;104:e209918.
    

    >> Share

    
    
76. SIEGLER JE, Galetta SL
    Editors' Note: Blood Astrocyte Biomarkers in Alzheimer Disease: A Systematic Review and Meta-Analysis.
    Neurology. 2025;104:e213477.
    

    >> Share

    
    
77. JIAO X, Liu X, Tian G
    Reader Response: Blood Astrocyte Biomarkers in Alzheimer Disease: A Systematic Review and Meta-Analysis.
    Neurology. 2025;104:e209897.
    

    >> Share

    
    
78. CAI W, Neitzel J, Glodzik L, Blacker D, et al
    Effect Modifiers of the Association of Blood Pressure With Brain Amyloid and Tau Pathology.
    Neurology. 2025;104:e213441.
    

    >> Share

    
    
79. TURPIN AL, Felisatti F, Chauveau L, Haudry S, et al
    Association Between Lifestyle at Different Life Periods and Brain Integrity in Older Adults.
    Neurology. 2025;104:e213347.
    

    >> Share

    
    
80. DE GEUS MB, Wu CY, Dodge H, Leslie SN, et al
    Unbiased CSF Proteomics in Patients With Idiopathic Normal Pressure Hydrocephalus to Identify Molecular Signatures and Candidate Biomarkers.
    Neurology. 2025;104:e213375.
    

    >> Share

    
    February 2025
81. LIANG J, Hussainy S, Lee SM, Wu G, et al
    Association of Polygenic Risk Score for 5 Diseases With Alzheimer Disease Progression, Biomarkers, and Amyloid Deposition.
    Neurology. 2025;104:e210250.
    

    >> Share

    
    
82. DARK HE, Shafer AT, Cordon J, An Y, et al
    Association of Plasma Biomarkers of Alzheimer Disease and Neurodegeneration With Longitudinal Intra-Network Functional Brain Connectivity.
    Neurology. 2025;104:e210271.
    

    >> Share

    
    
83. BORNHORST JA, Lundgreen CS, Weigand SD, Figdore DJ, et al
    Quantitative Assessment of the Effect of Chronic Kidney Disease on Plasma P-Tau217 Concentrations.
    Neurology. 2025;104:e210287.
    

    >> Share

    
    January 2025
84. QUISPIALAYA KM, Therriault J, Aliaga A, Benedet AL, et al
    Comparison of Plasma p-tau217 and [(18)F]FDG-PET for Identifying Alzheimer Disease in People With Early-Onset or Atypical Dementia.
    Neurology. 2025;104:e210211.
    

    >> Share

    
    
85. MOROTTI A, Pilotto A, Zanola D, Galli A, et al
    Cerebral Amyloid Angiopathy in Alzheimer Disease: A Comparison Between Different Versions of the Boston Criteria.
    Neurology. 2025;104:e210248.
    

    >> Share

    
    
86. RODRIGUEZ-BAZ I, Benejam B, Morcillo-Nieto AO, Vaque-Alcazar L, et al
    Posterior Cortical Atrophy Due to Alzheimer Disease in a Person With Down Syndrome: A Case Report.
    Neurology. 2025;104:e210179.
    

    >> Share

    
    
87. GRILL JD, Tam S, Thai G, Vides B, et al
    Phase 2A Proof-of-Concept Double-Blind, Randomized, Placebo-Controlled Trial of Nicotinamide in Early Alzheimer Disease.
    Neurology. 2025;104:e210152.
    

    >> Share

    
    
88. LEE S, Rajmohan R, Al-Darsani Z, Paganini-Hill A, et al
    Medical Histories Associated With Absence of Alzheimer Disease Neuropathologic Changes in the Oldest-Old: The 90+ Study.
    Neurology. 2025;104:e210107.
    

    >> Share

    
    
89. 
    Association of Seizure Foci and Location of Tau and Amyloid Deposition and Brain Atrophy in Patients With Alzheimer Disease and Seizures.
    Neurology. 2025;104:e210173.
    

    >> Share

    
    December 2024
90. BOCCALINI C, Dodich A, Scheffler M, Lagana V, et al
    In Vivo Tau and Neurodegeneration Imaging in a Family With the Presenilin 1 Met146Leu Pathogenic Variant.
    Neurology. 2024;103:e210103.
    

    >> Share

    
    
91. 
    Challenges in a Biological Definition of Alzheimer Disease.
    Neurology. 2024;103:e210200.
    

    >> Share

    
    
92. BISCHOF GN, Jaeger E, Giehl K, Jessen F, et al
    Cortical Tau Aggregation Patterns Associated With Apraxia in Patients With Alzheimer Disease.
    Neurology. 2024;103:e210062.
    

    >> Share

    
    
93. SAFRANSKY M, Groh JR, Blennow K, Zetterberg H, et al
    Lumipulse-Measured Cerebrospinal Fluid Biomarkers for the Early Detection of Alzheimer Disease.
    Neurology. 2024;103:e209866.
    

    >> Share

    
    November 2024
94. SIN MK, Cheng Y, Ahmed A, Roseman JM, et al
    Cerebral Amyloid Angiopathy, Dementia, and Alzheimer Neuropathologic Changes: Findings From the ACT Autopsy Cohort.
    Neurology. 2024;103:e210009.
    

    >> Share

    
    
95. GUSOVSKY AV, Lin CC, Kerber K, Reynolds EL, et al
    Costs Are Still on the Rise for Commonly Prescribed Branded Neurologic Medications.
    Neurology. 2024;103:e210029.
    

    >> Share

    
    
96. LAM AD, Thibault EG, Mayblyum DV, Hsieh S, et al
    Association of Seizure Foci and Location of Tau and Amyloid Deposition and Brain Atrophy in Patients With Alzheimer Disease and Seizures.
    Neurology. 2024;103:e209920.
    

    >> Share

    
    
97. HAZAN J, Liu KY, Costello H, Isaacs JD, et al
    Challenges in a Biological Definition of Alzheimer Disease.
    Neurology. 2024;103:e209884.
    

    >> Share

    
    
98. JAGUST WJ
    Alzheimer Disease Is a Specific Disorder Defined by Neuropathology Detectable During Life.
    Neurology. 2024;103:e209995.
    

    >> Share

    
    
99. AAMODT WW, Sun C, Dahodwala N, Elser H, et al
    End-of-Life Health Care Service Use and Cost Among Medicare Decedents With Neurodegenerative Diseases.
    Neurology. 2024;103:e209925.
    

    >> Share

    
    October 2024
100. 
     Associations of Microbleeds and Their Topography With Imaging and CSF Biomarkers of Alzheimer Pathology in Individuals With Down Syndrome.
     Neurology. 2024;103:e209935.
     

     >> Share

     
     
101. WANG YY, Wang YJ, Zeng F
     Case of Autosomal-Dominant Alzheimer Disease With Ribbon-Like Cortical Calcifications.
     Neurology. 2024;103:e209860.
     

     >> Share

     
     
102. LORENZINI L, Maranzano A, Ingala S, Collij LE, et al
     Association of Vascular Risk Factors and Cerebrovascular Pathology With Alzheimer Disease Pathologic Changes in Individuals Without Dementia.
     Neurology. 2024;103:e209801.
     

     >> Share

     
     
103. CHARIDIMOU A, Boulouis G
     Core CSF Biomarker Profile in Cerebral Amyloid Angiopathy: Updated Meta-Analysis.
     Neurology. 2024;103:e209795.
     

     >> Share

     
     
104. SON HJ, Kim JS, Bateman RJ, Kim S, et al
     Association of Resilience-Related Life Experiences on Variability on Age of Onset in Dominantly Inherited Alzheimer Disease.
     Neurology. 2024;103:e209766.
     

     >> Share

     
     September 2024
105. ANASTASSIADIS C, Martinez-Valbuena I, Vasilevskaya A, Thapa S, et al
     CSF alpha-Synuclein Seed Amplification Assay in Patients With Atypical Parkinsonian Disorders.
     Neurology. 2024;103:e209818.
     

     >> Share

     
     
106. NEVES BRIARD J, Duquette A, Cayrol R, Lapalme-Remis S, et al
     Refractory Status Epilepticus in a Patient With Aducanumab-Induced Amyloid-Related Imaging Abnormalities.
     Neurology. 2024;103:e209582.
     

     >> Share

     
     
107. LENNON MJ, Lipnicki DM, Lam BCP, Crawford JD, et al
     Blood Pressure, Antihypertensive Use, and Late-Life Alzheimer and Non-Alzheimer Dementia Risk: An Individual Participant Data Meta-Analysis.
     Neurology. 2024;103:e209715.
     

     >> Share

     
     
108. VILLAIN N, Paretsky MS
     The Great Debate in Diagnosing Alzheimer Disease: More Than Just a beta Test.
     Neurology. 2024;103:e209836.
     

     >> Share

     
     
109. BIEGER A, Brum WS, Borelli WV, Therriault J, et al
     Influence of Different Diagnostic Criteria on Alzheimer Disease Clinical Research.
     Neurology. 2024;103:e209753.
     

     >> Share

     
     August 2024
110. KRUGER J, Aaltonen M, Aho K, Heikkinen S, et al
     Incidence and Prevalence of Early-Onset Dementia in Finland.
     Neurology. 2024;103:e209654.
     

     >> Share

     
     
111. INGRAM RU, Ocal D, Halai A, Pobric G, et al
     Graded Multidimensional Clinical and Radiologic Variation in Patients With Alzheimer Disease and Posterior Cortical Atrophy.
     Neurology. 2024;103:e209679.
     

     >> Share

     
     
112. ZSADANYI SE, Morcillo-Nieto AO, Aranha MR, Aragon I, et al
     Associations of Microbleeds and Their Topography With Imaging and CSF Biomarkers of Alzheimer Pathology in Individuals With Down Syndrome.
     Neurology. 2024;103:e209676.
     

     >> Share

     
     
113. GANESH A, Galetta SL
     Editors' Note: Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging.
     Neurology. 2024;103:e209634.
     

     >> Share

     
     
114. CONNOLLY E, O'Connor A, Fallon A, O'Dowd S, et al
     Reader Response: Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging.
     Neurology. 2024;103:e209343.
     

     >> Share

     
     
115. VASSILAKI M, Graff-Radford J
     Author Response: Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging.
     Neurology. 2024;103:e209371.
     

     >> Share

     
     
116. HOLPER S, Loveland P, Churilov L, Italiano D, et al
     Blood Astrocyte Biomarkers in Alzheimer Disease: A Systematic Review and Meta-Analysis.
     Neurology. 2024;103:e209537.
     

     >> Share

     
     July 2024
117. HAMILTON CA, Donaghy PC, Durcan R, Ciafone J, et al
     Outcomes of Patients With Mild Cognitive Impairment With Lewy Bodies or Alzheimer Disease at 3 and 5 Years After Diagnosis.
     Neurology. 2024;103:e209499.
     

     >> Share

     
     
118. XIA Y, Dore V, Fripp J, Bourgeat P, et al
     Association of Basal Forebrain Atrophy With Cognitive Decline in Early Alzheimer Disease.
     Neurology. 2024;103:e209626.
     

     >> Share

     
     
119. MASTENBROEK SE, Sala A, Vallez Garcia D, Shekari M, et al
     Continuous beta-Amyloid CSF/PET Imbalance Model to Capture Alzheimer Disease Heterogeneity.
     Neurology. 2024;103:e209419.
     

     >> Share

     
     June 2024
120. DUBINSKY RM, Stein AC
     Predicting Driving Cessation in Alzheimer Disease: Performance Beats Biomarkers.
     Neurology. 2024;102:e209523.
     

     >> Share

     
     
121. BABULAL GM, Chen L, Murphy SA, Carr DB, et al
     Predicting Driving Cessation Among Cognitively Normal Older Drivers: The Role of Alzheimer Disease Biomarkers and Clinical Assessments.
     Neurology. 2024;102:e209426.
     

     >> Share

     
     
122. YE R, Goodheart AE, Locascio JJ, Peterec E, et al
     Differential Vulnerability of Hippocampal Subfields to Amyloid and Tau Deposition in the Lewy Body Diseases.
     Neurology. 2024;102:e209460.
     

     >> Share

     
     
123. JADICK MF, Robinson T, Farrell ME, Klinger H, et al
     Associations Between Self and Study Partner Report of Cognitive Decline With Regional Tau in a Multicohort Study.
     Neurology. 2024;102:e209447.
     

     >> Share

     
     
124. SUN M, He Q, Sun N, Han Q, et al
     Intrinsic Capacity, Polygenic Risk Score, APOE Genotype, and Risk of Dementia: A Prospective Cohort Study Based on the UK Biobank.
     Neurology. 2024;102:e209452.
     

     >> Share

     
     
125. BOLSEWIG K, van Unnik AAJM, Blujdea ER, Gonzalez MC, et al
     Association of Plasma Amyloid, P-Tau, GFAP, and NfL With CSF, Clinical, and Cognitive Features in Patients With Dementia With Lewy Bodies.
     Neurology. 2024;102:e209418.
     

     >> Share

     
     May 2024
126. DITTRICH A, Westman E, Shams S, Skillback T, et al
     Proportion of Community-Dwelling Individuals Older Than 70 Years Eligible for Lecanemab Initiation: The Gothenburg H70 Birth Cohort Study.
     Neurology. 2024;102:e209402.
     

     >> Share

     
     
127. VASSILAKI M, Pittock RR, Aakre JA, Castillo AM, et al
     Author Response: Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging.
     Neurology. 2024;102:e209377.
     

     >> Share

     
     
128. CHIABOTTI PS, Rouaud O, Allali G
     Reader Response: Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging.
     Neurology. 2024;102:e209375.
     

     >> Share

     
     
129. LEWIS A, Galetta S
     Editors' Note: Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging.
     Neurology. 2024;102:e209376.
     

     >> Share

     
     
130. WOOD ALEXANDER M, Wu CY, Coughlan GT, Puri T, et al
     Associations Between Age at Menopause, Vascular Risk, and 3-Year Cognitive Change in the Canadian Longitudinal Study on Aging.
     Neurology. 2024;102:e209298.
     

     >> Share

     
     
131. GRASSET L, Bouteloup V, Cacciamani F, Pellegrin I, et al
     Associations Between Blood-Based Biomarkers and Cognitive and Functional Trajectories Among Participants of the MEMENTO Cohort.
     Neurology. 2024;102:e209307.
     

     >> Share

     
     April 2024
132. BUCKLEY RF, Schindler SE
     Lower Accuracy Alzheimer Disease Blood Tests Will Never Be "Ready for Prime Time".
     Neurology. 2024;102:e209295.
     

     >> Share

     
     
133. BOUTELOUP V, Pellegrin I, Dubois B, Chene G, et al
     Explaining the Variability of Alzheimer Disease Fluid Biomarker Concentrations in Memory Clinic Patients Without Dementia.
     Neurology. 2024;102:e209219.
     

     >> Share

     
     
134. RAJAN KB, Mcaninch EA, Wilson RS, Dhana A, et al
     Statin Initiation and Risk of Incident Alzheimer Disease and Cognitive Decline in Genetically Susceptible Older Adults.
     Neurology. 2024;102:e209168.
     

     >> Share

     
     
135. ASKEN BM, Tanner JA, Vandevrede L, Apple A, et al
     Linking Type and Extent of Head Trauma to Cavum Septum Pellucidum in Older Adults With and Without Alzheimer Disease and Related Dementias.
     Neurology. 2024;102:e209183.
     

     >> Share

     
     
136. NELSON SE, Lopez OL
     Lecanemab for Alzheimer Disease: Is It Worth It?
     Neurology. 2024;102:e209265.
     

     >> Share

     
     
137. NADEAU SE
     Lecanemab Questions.
     Neurology. 2024;102:e209320.
     

     >> Share

     
     
138. NGUYEN HV, Mital S, Knopman DS, Alexander GC, et al
     Cost-Effectiveness of Lecanemab for Individuals With Early-Stage Alzheimer Disease.
     Neurology. 2024;102:e209218.
     

     >> Share

     
     
139. ALOSCO ML, Tartaglia MC
     Repetitive Blast Injury and CSF Alzheimer Disease Biomarkers: Navigating a Complex Narrative.
     Neurology. 2024;102:e209294.
     

     >> Share

     
     
140. LI G, Iliff J, Shofer J, Mayer CL, et al
     CSF beta-Amyloid and Tau Biomarker Changes in Veterans With Mild Traumatic Brain Injury.
     Neurology. 2024;102:e209197.
     

     >> Share

     
     
141. OVEISGHARAN S, Grodstein F, Evia AM Jr, James BD, et al
     Association of Age-Related Neuropathologic Findings at Autopsy With a Claims-Based Epilepsy Diagnosis in Older Adults.
     Neurology. 2024;102:e209172.
     

     >> Share

     
     
142. WEINSTEIN G, Kojis DJ, Ghosh S, Beiser AS, et al
     Association of Neurotrophic Factors at Midlife With In Vivo Measures of beta-Amyloid and Tau Burden 15 Years Later in Dementia-Free Adults.
     Neurology. 2024;102:e209198.
     

     >> Share

     
     
143. LU Y, Pike JR, Hoogeveen R, Walker K, et al
     Nonalcoholic Fatty Liver Disease and Longitudinal Change in Imaging and Plasma Biomarkers of Alzheimer Disease and Vascular Pathology.
     Neurology. 2024;102:e209203.
     

     >> Share

     
     
144. BUCHMAN AS, Yu L, Klein HU, Zammit AR, et al
     Glycoproteome-Wide Discovery of Cortical Glycoproteins That May Provide Cognitive Resilience in Older Adults.
     Neurology. 2024;102:e209223.
     

     >> Share

     
     
145. CAI Y, Shi D, Lan G, Chen L, et al
     Association of beta-Amyloid, Microglial Activation, Cortical Thickness, and Metabolism in Older Adults Without Dementia.
     Neurology. 2024;102:e209205.
     

     >> Share

     
     
146. SCHELTENS P, Atri A, Feldman H, Hansson O, et al
     Baseline Characteristics from Evoke and Evoke+: Two Phase 3 Randomized Placebo-controlled Trials of Oral Semaglutide in Patients with Early Alzheimer's Disease (P11-9.013).
     Neurology. 2024;102.
     

     >> Share

     
     
147. HENEKA M, Gauthier S, Chandekar SA, Hahn-Pedersen JH, et al
     The Role of Neuroinflammation in Alzheimer's Disease: A Systematic Literature Review (P7-9.013).
     Neurology. 2024;102.
     

     >> Share

     
     
148. GREENBERG S, Battioui C, Lu M, Biffi A, et al
     ARIA Insights from the Donanemab Trials (P1-9.001).
     Neurology. 2024;102.
     

     >> Share

     
     
149. BERTON G, Moreira M, Rodrigues ACLF, Donadon IB, et al
     Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Sleep Deprived Patients: A Systematic Review and Meta-analysis (P8-9.008).
     Neurology. 2024;102.
     

     >> Share

     
     
150. APPLETON J, Funk Q, Fregonara PZ, Yu M, et al
     Neuroinflammation Co-localizes Highly with Tau in Mild Cognitive Impairment from Early Onset Alzheimer's Disease (N4.002).
     Neurology. 2024;102.
     

     >> Share

     
     
151. SAHAY S, Imami A, Hamoud A, McCullumsmith R, et al
     Towards Timely Alzheimer's Diagnosis: A Clinical Data-Driven Approach to Biomarker Discovery (P7-9.016).
     Neurology. 2024;102.
     

     >> Share

     
     March 2024
152. HONIG M, Altomare D, Caprioglio C, Collij L, et al
     Association Between Years of Education and Amyloid Burden in Patients With Subjective Cognitive Decline, MCI, and Alzheimer Disease.
     Neurology. 2024;102:e208053.
     

     >> Share

     
     
153. ACKLEY S, Calmasini C, Bouteloup V, Hill-Jarrett TG, et al
     Contribution of Global Amyloid-PET Imaging for Predicting Future Cognition in the MEMENTO Cohort.
     Neurology. 2024;102:e208054.
     

     >> Share

     
     
154. GUO C, Harshfield EL, Markus HS
     Sleep Characteristics and Risk of Stroke and Dementia: An Observational and Mendelian Randomization Study.
     Neurology. 2024;102:e209141.
     

     >> Share

     
     
155. FLEISHER AS, Munsie LM, Perahia DGS, Andersen SW, et al
     Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease.
     Neurology. 2024;102:e208061.
     

     >> Share

     
     
156. CHRISTENSEN GM, Li Z, Liang D, Ebelt S, et al
     Association of PM(2.5) Exposure and Alzheimer Disease Pathology in Brain Bank Donors-Effect Modification by APOE Genotype.
     Neurology. 2024;102:e209162.
     

     >> Share

     
     February 2024
157. HILL-JARRETT TG, Choi M, Buto PT, Miramontes S, et al
     Associations of Everyday and Lifetime Experiences of Discrimination With Willingness to Undergo Alzheimer Disease Predictive Testing.
     Neurology. 2024;102:e208005.
     

     >> Share

     
     
158. PASE MP, Himali JJ, Puerta R, Beiser AS, et al
     Association of Plasma YKL-40 With MRI, CSF, and Cognitive Markers of Brain Health and Dementia.
     Neurology. 2024;102:e208075.
     

     >> Share

     
     
159. YASAR S, Nidadavolu L
     Repurposing Erectile Dysfunction Medication for Alzheimer Disease Prevention.
     Neurology. 2024;102:e209180.
     

     >> Share

     
     
160. ADESUYAN M, Jani YH, Alsugeir D, Howard R, et al
     Phosphodiesterase Type 5 Inhibitors in Men With Erectile Dysfunction and the Risk of Alzheimer Disease: A Cohort Study.
     Neurology. 2024;102:e209131.
     

     >> Share

     
     
161. SHINOTOH H
     White Matter Neuroinflammation Matters in Early Alzheimer Disease.
     Neurology. 2024;102:e208090.
     

     >> Share

     
     
162. TARAWNEH R
     YKL-40 as a New Plasma Biomarker for Dementia Risk: Are We There Yet?
     Neurology. 2024;102:e209145.
     

     >> Share

     
     
163. HARDY J, Schott JM
     Identifying Genetic Risk for Amyloid-Related Imaging Abnormalities.
     Neurology. 2024;102:e208096.
     

     >> Share

     
     
164. LOOMIS SJ, Miller R, Castrillo-Viguera C, Umans K, et al
     Genome-Wide Association Studies of ARIA From the Aducanumab Phase 3 ENGAGE and EMERGE Studies.
     Neurology. 2024;102:e207919.
     

     >> Share

     
     
165. CHOLERTON B, Latimer CS, Crane PK, Corrada MM, et al
     Neuropathologic Burden and Dementia in Nonagenarians and Centenarians.
     Neurology. 2024;102:e208060.
     

     >> Share

     
     
166. PARK SY, Setiawan VW, Crimmins EM, White LR, et al
     Racial and Ethnic Differences in the Population-Attributable Fractions of Alzheimer Disease and Related Dementias.
     Neurology. 2024;102:e208116.
     

     >> Share

     
     
167. WANG Q, Schindler SE, Chen G, Mckay NS, et al
     Investigating White Matter Neuroinflammation in Alzheimer Disease Using Diffusion-Based Neuroinflammation Imaging.
     Neurology. 2024;102:e208013.
     

     >> Share

     
     
168. COUSINS KAQ, Irwin DJ, Tropea TF, Rhodes E, et al
     Evaluation of ATN(PD) Framework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson Disease.
     Neurology. 2024;102:e208033.
     

     >> Share

     
     January 2024
169. CASTILHOS RM, Snitz BE
     Longitudinal Cognitive Decline in Alzheimer Disease Prevention Trials.
     Neurology. 2024;102:e208067.
     

     >> Share

     
     
170. DUBBELMAN MA, Hendriksen HMA, Harrison JE, Vijverberg EGB, et al
     Cognitive and Functional Change Over Time in Cognitively Healthy Individuals According to Alzheimer Disease Biomarker-Defined Subgroups.
     Neurology. 2024;102:e207978.
     

     >> Share

     
     
171. LOPEZ OL, Villemagne VL, Chang YF, Cohen AD, et al
     Association Between beta-Amyloid Accumulation and Incident Dementia in Individuals 80 Years or Older Without Dementia.
     Neurology. 2024;102:e207920.
     

     >> Share

     
     
172. PEROSA V, Zanon Zotin MC, Schoemaker D, Sveikata L, et al
     Association Between Hippocampal Volumes and Cognition in Cerebral Amyloid Angiopathy.
     Neurology. 2024;102:e207854.
     

     >> Share

     
     
173. ZANON ZOTIN MC, Makkinejad N, Schneider JA, Arfanakis K, et al
     Sensitivity and Specificity of the Boston Criteria Version 2.0 for the Diagnosis of Cerebral Amyloid Angiopathy in a Community-Based Sample.
     Neurology. 2024;102:e207940.
     

     >> Share

     
     December 2023
174. HANSEEUW BJ, Jacobs HIL, Schultz AP, Buckley RF, et al
     Association of Pathologic and Volumetric Biomarker Changes With Cognitive Decline in Clinically Normal Adults.
     Neurology. 2023;101:e2533-e2544.
     

     >> Share

     
     November 2023
175. ZHOU Z, Ryan J, Tonkin AM, Zoungas S, et al
     Association Between Triglycerides and Risk of Dementia in Community-Dwelling Older Adults: A Prospective Cohort Study.
     Neurology. 2023;101:e2288-e2299.
     

     >> Share

     
     
176. YOON SH, Kim HK, Lee JH, Chun JH, et al
     Association of Sleep Disturbances With Brain Amyloid and Tau Burden, Cortical Atrophy, and Cognitive Dysfunction Across the AD Continuum.
     Neurology. 2023;101:e2162-e2171.
     

     >> Share

     
     
177. FERGUSON EL, Zimmerman SC, Jiang C, Choi M, et al
     Low- and High-Density Lipoprotein Cholesterol and Dementia Risk Over 17 Years of Follow-up Among Members of a Large Health Care Plan.
     Neurology. 2023;101:e2172-e2184.
     

     >> Share

     
     
178. NELSON PT, Jicha GA
     Early Hippocampal Atrophy Is an Important Signal for Clinicians, but Not Necessarily a Harbinger of Alzheimer Disease.
     Neurology. 2023 Nov 15:10.1212/WNL.0000000000208071.
     

     >> Share

     
     
179. PITTOCK RR, Aakre JA, Castillo AM, Ramanan VK, et al
     Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging.
     Neurology. 2023;101:e1837-e1849.
     

     >> Share

     
     
180. HOWE MD, Rabinovici GD, Salloway SP
     Real-World Application of Anti-beta-Amyloid Monoclonal Antibodies: Untangling Eligibility.
     Neurology. 2023;101:811-812.
     

     >> Share

     
     October 2023
181. THEIS H, Bischof GN, Bruggemann N, Dargvainiene J, et al
     In Vivo Measurement of Tau Depositions in Anti-IgLON5 Disease Using (18)F-PI-2620 PET.
     Neurology. 2023 Oct 25:10.1212/WNL.0000000000207870.
     

     >> Share

     
     
182. ALAM JJ, Maruff P, Doctrow SR, Chu HM, et al
     Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy Bodies.
     Neurology. 2023;101:e1708-e1717.
     

     >> Share

     
     
183. SANTAMARIA BA, Corroza J, Sanchez-Ruiz de Gordoa J, Cabello C, et al
     Association of Blood-Based DNA Methylation Markers With Late-Onset Alzheimer Disease: A Potential Diagnostic Approach.
     Neurology. 2023 Oct 12:10.1212/WNL.0000000000207865.
     

     >> Share

     
     
184. STARK M, Wolfsgruber S, Kleineidam L, Frommann I, et al
     Relevance of Minor Neuropsychological Deficits in Patients With Subjective Cognitive Decline.
     Neurology. 2023 Oct 11:10.1212/WNL.0000000000207844.
     

     >> Share

     
     
185. GONZALES MM, Vela G, Philip V, Trevino H, et al
     Demographic and Clinical Characteristics Associated With Serum GFAP Levels in an Ethnically Diverse Cohort.
     Neurology. 2023;101:e1531-e1541.
     

     >> Share

     
     
186. OVEISGHARAN S, Yu L, Agrawal S, Nag S, et al
     Relation of Motor Impairments to Neuropathologic Changes of Limbic-Predominant Age-Related TDP-43 Encephalopathy in Older Adults.
     Neurology. 2023;101:e1542-e1553.
     

     >> Share

     
     
187. BONOMI S, Samara A, Balestra N, Padalia A, et al
     Teaching NeuroImage: Severe Amyloid-Related Imaging Abnormalities After Anti-beta-Amyloid Monoclonal Antibody Treatment.
     Neurology. 2023 Oct 10:10.1212/WNL.0000000000207927.
     

     >> Share

     
     
188. BRENNER S
     Reader Response: Estrogen Receptor Genes, Cognitive Decline, and Alzheimer Disease.
     Neurology. 2023;101:633-634.
     

     >> Share

     
     
189. OVEISGHARAN S, Bennett DA
     Author Response: Estrogen Receptor Genes, Cognitive Decline, and Alzheimer Disease.
     Neurology. 2023;101:634.
     

     >> Share

     
     
190. GANESH A, Galetta S
     Editors' Note: Estrogen Receptor Genes, Cognitive Decline, and Alzheimer Disease.
     Neurology. 2023;101:633.
     

     >> Share

     
     
191. LEWIS A, Gupta A, Oh I, Schindler SE, et al
     Association Between Socioeconomic Factors, Race, and Use of a Specialty Memory Clinic.
     Neurology. 2023;101:e1424-e1433.
     

     >> Share

     
     September 2023
192. GOODSMITH MS, Wroblewski KE, Schumm LP, McClintock MK, et al
     Association of APOE epsilon4 Status With Long-term Declines in Odor Sensitivity, Odor Identification, and Cognition in Older US Adults.
     Neurology. 2023;101:e1341-e1350.
     

     >> Share

     
     
193. COOMANS EM, de Koning LA, Rikken RM, Verfaillie SC, et al
     Performance of a [(18)F]Flortaucipir PET Visual Read Method Across the Alzheimer Disease Continuum and in Dementia With Lewy Bodies.
     Neurology. 2023 Sep 25:10.1212/WNL.0000000000207794.
     

     >> Share

     
     
194. MALPETTI M, Rabinovici GD
     From Clinical Trials to Memory Clinics, tau-PET Visual Reads Can Help Diagnosis and Patient Stratification.
     Neurology. 2023 Sep 25:10.1212/WNL.0000000000207935.
     

     >> Share

     
     
195. YAMAGUCHI S, Murakami T, Satoh M, Komiyama T, et al
     Associations of Dental Health With the Progression of Hippocampal Atrophy in Community-Dwelling Individuals: The Ohasama Study.
     Neurology. 2023;101:e1056-e1068.
     

     >> Share

     
     August 2023
196. MONTEIRO C, Toth B, Brunstein F, Bobbala A, et al
     A Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants with Mild-to-Moderate Alzheimer's Disease (Lauriet).
     Neurology. 2023 Aug 29:10.1212/WNL.0000000000207663.
     

     >> Share

     
     
197. EDLAND SD, Ucsd, Llibre-Guerra JJ
     Semorinemab in Mild to Moderate Alzheimer Disease: A Glimmer of Hope Though Cautions Remain.
     Neurology. 2023 Aug 29:10.1212/WNL.0000000000207861.
     

     >> Share

     
     
198. KAMAL F, Morrison C, Maranzano J, Zeighami Y, et al
     White Matter Hyperintensity Trajectories in Patients With Progressive and Stable Mild Cognitive Impairment.
     Neurology. 2023;101:e815-e824.
     

     >> Share

     
     
199. PARNETTI L, Bellomo G
     Advances in Diagnosis and Prognosis of Parkinson Disease: Value of Cerebrospinal Fluid Proteomics.
     Neurology. 2023 Aug 16:10.1212/WNL.0000000000207724.
     

     >> Share

     
     
200. KAWADA T
     Reader Response: Predicting Cognitive Decline in Older Adults Using Baseline Metrics of AD Pathologies, Cerebrovascular Disease, and Neurodegeneration.
     Neurology. 2023;101:333-334.
     

     >> Share

     
     
201. PROSSER L
     Author Response: Predicting Cognitive Decline in Older Adults Using Baseline Metrics of AD Pathologies, Cerebrovascular Disease, and Neurodegeneration.
     Neurology. 2023;101:334.
     

     >> Share

     
     
202. LEWIS A, Galetta S
     Editors' Note: Predicting Cognitive Decline in Older Adults Using Baseline Metrics of AD Pathologies, Cerebrovascular Disease, and Neurodegeneration.
     Neurology. 2023;101:333.
     

     >> Share

     
     
203. RAMANAN VK, Graff-Radford J, Syrjanen J, Shir D, et al
     Association of Plasma Biomarkers of Alzheimer Disease With Cognition and Medical Comorbidities in a Biracial Cohort.
     Neurology. 2023 Aug 14:10.1212/WNL.0000000000207675.
     

     >> Share

     
     
204. CATHARINA BOON BD, Labuzan S, Peng Z, Matchett B, et al
     Retrospective Evaluation of Neuropathologic Proxies of the Minimal Atrophy Subtype Compared to Corticolimbic Alzheimer Disease Subtypes.
     Neurology. 2023 Aug 14:10.1212/WNL.0000000000207685.
     

     >> Share

     
     
205. LAM AD
     Linking Late-Onset Epilepsy With Alzheimer Disease: Insights From Plasma Amyloid Measurements.
     Neurology. 2023 Aug 4:10.1212/WNL.0000000000207683.
     

     >> Share

     
     
206. JOHNSON EL, Sullivan KJ, Schneider ALC, Simino J, et al
     Association of Plasma Abeta 42/40 Ratio and Late-Onset Epilepsy: Results From the Atherosclerosis Risk in Communities Study.
     Neurology. 2023 Aug 4:10.1212/WNL.0000000000207635.
     

     >> Share

     
     
207. HADDAD A, Brunel G, Indart S, Paquet C, et al
     A Patient With the Posterior Variant of Alzheimer Disease Plays Table Tennis: Blindsight and Pingpong.
     Neurology. 2023 Aug 3:10.1212/WNL.0000000000207650.
     

     >> Share

     
     July 2023
208. DURCAN R, Roberts G, Hamilton CA, Donaghy PC, et al
     Serial Nigrostriatal Dopaminergic Imaging in Mild Cognitive Impairment With Lewy Bodies, Alzheimer Disease, and Age-Matched Controls.
     Neurology. 2023 Jul 31:10.1212/WNL.0000000000207621.
     

     >> Share

     
     
209. RAMANAN VK, Armstrong MJ, Choudhury P, Coerver K, et al
     Antiamyloid Monoclonal Antibody Therapy for Alzheimer Disease: Emerging Issues in Neurology.
     Neurology. 2023 Jul 26:10.1212/WNL.0000000000207757.
     

     >> Share

     
     
210. PROKOPIOU PC, Engels-Dominguez N, Schultz AP, Sepulcre J, et al
     Association of Novelty-Related Locus Coeruleus Function With Entorhinal Tau Deposition and Memory Decline in Preclinical Alzheimer Disease.
     Neurology. 2023 Jul 25:10.1212/WNL.0000000000207646.
     

     >> Share

     
     
211. KARCESKI S, Antonopoulos M
     Biomarkers in Alzheimer Disease: A Review.
     Neurology. 2023;101:e461-e463.
     

     >> Share

     
     
212. ANDRE C, Kuhn E, Rehel S, Ourry V, et al
     Association of Sleep-Disordered Breathing and Medial Temporal Lobe Atrophy in Cognitively Unimpaired Amyloid-Positive Older Adults.
     Neurology. 2023;101:e370-e385.
     

     >> Share

     
     
213. ALCOLEA D, Beeri MS, Rojas JC, Gardner RC, et al
     Blood Biomarkers in Neurodegenerative Diseases: Implications for the Clinical Neurologist.
     Neurology. 2023;101:172-180.
     

     >> Share

     
     
214. BURKE JF, Richard S, Langa KM, Albin RL, et al
     Lecanemab: Looking Before We Leap.
     Neurology. 2023 Jul 21:10.1212/WNL.0000000000207505.
     

     >> Share

     
     
215. SHIR D, Pham NTT, Botha H, Koga S, et al
     Clinicoradiologic and Neuropathologic Evaluation of Corticobasal Syndrome.
     Neurology. 2023;101:e289-e299.
     

     >> Share

     
     
216. DITTRICH A, Ashton NJ, Zetterberg H, Blennow K, et al
     Association of Chronic Kidney Disease With Plasma NfL and Other Biomarkers of Neurodegeneration: The H70 Birth Cohort Study in Gothenburg.
     Neurology. 2023;101:e277-e288.
     

     >> Share

     
     
217. MOSER ED, Manemann SM, Larson NB, St Sauver JL, et al
     Association Between Fluctuations in Blood Lipid Levels Over Time With Incident Alzheimer Disease and Alzheimer Disease Related Dementias.
     Neurology. 2023 Jul 5:10.1212/WNL.0000000000207595.
     

     >> Share

     
     
218. BARBA L, Abu-Rumeileh S, Halbgebauer S, Bellomo G, et al
     CSF Synaptic Biomarkers in AT(N)-Based Subgroups of Lewy Body Disease.
     Neurology. 2023;101:e50-e62.
     

     >> Share

     
     
219. FERREIRA PCL, Ferrari-Souza JP, Tissot C, Bellaver B, et al
     Potential Utility of Plasma P-Tau and Neurofilament Light Chain as Surrogate Biomarkers for Preventive Clinical Trials.
     Neurology. 2023;101:38-45.
     

     >> Share

     
     
220. LICHTER DG, Hershey L
     Proposal to Add FDG-PET as an Outcome Measure for Clinical Trials in Patients With Prodromal Lewy Body Dementia.
     Neurology. 2023 Jul 3:10.1212/WNL.0000000000207498.
     

     >> Share

     
     June 2023
221. KNOPMAN DS, Hershey L
     Implications of the Approval of Lecanemab for Alzheimer Disease Patient Care: Incremental Step or Paradigm Shift.
     Neurology. 2023 Jun 9:10.1212/WNL.0000000000207438.
     

     >> Share

     
     May 2023
222. GROBER E, Petersen KK, Lipton RB, Hassenstab J, et al
     Association of Stages of Objective Memory Impairment With Incident Symptomatic Cognitive Impairment in Cognitively Normal Individuals.
     Neurology. 2023;100:e2279-e2289.
     

     >> Share

     
     
223. FANG Y, Si X, Wang J, Wang Z, et al
     Alzheimer Disease and Epilepsy: A Mendelian Randomization Study.
     Neurology. 2023 May 24:10.1212/WNL.0000000000207423.
     

     >> Share

     
     
224. LUO J, Ma Y, Agboola FJ, Grant E, et al
     Longitudinal Relationships of White Matter Hyperintensities and Alzheimer Disease Biomarkers Across the Adult Lifespan.
     Neurology. 2023 May 18:10.1212/WNL.0000000000207378.
     

     >> Share

     
     
225. DIAZ-GALVAN P, Przybelski SA, Lesnick TG, Schwarz CG, et al
     beta-Amyloid Load on PET Along the Continuum of Dementia With Lewy Bodies.
     Neurology. 2023 May 18:10.1212/WNL.0000000000207393.
     

     >> Share

     
     
226. ALVES F, Kalinowski P, Ayton S
     Accelerated Brain Volume Loss Caused by Anti-beta-Amyloid Drugs: A Systematic Review and Meta-analysis.
     Neurology. 2023;100:e2114-e2124.
     

     >> Share

     
     
227. DU J, Li A, Shi D, Chen X, et al
     Association of APOE4, Osteoarthritis, beta-Amyloid, and Tau Accumulation in Primary Motor and Somatosensory Regions in Alzheimer Disease.
     Neurology. 2023 May 15:10.1212/WNL.0000000000207369.
     

     >> Share

     
     
228. BUTLER PAGNOTTI RM, Pudumjee SB, Cross CL, Miller JB, et al
     Cognitive and Clinical Characteristics of Patients With Limbic-Predominant Age-Related TDP-43 Encephalopathy.
     Neurology. 2023;100:e2027-e2035.
     

     >> Share

     
     
229. CICOGNOLA C, Mattsson-Carlgren N, van Westen D, Zetterberg H, et al
     Associations of CSF PDGFRbeta With Aging, Blood-Brain Barrier Damage, Neuroinflammation, and Alzheimer Disease Pathologic Changes.
     Neurology. 2023 May 3:10.1212/WNL.0000000000207358.
     

     >> Share

     
     
230. SINHA N, Gugger JJ
     Towards a Patient-Specific Readout of Neurodegeneration: The Case for Spatial Normative Modeling in Alzheimer Disease.
     Neurology. 2023 May 1:10.1212/WNL.0000000000207280.
     

     >> Share

     
     
231. VERDI S, Kia SM, Yong KXX, Tosun D, et al
     Revealing Individual Neuroanatomical Heterogeneity in Alzheimer Disease Using Neuroanatomical Normative Modeling.
     Neurology. 2023 May 1:10.1212/WNL.0000000000207298.
     

     >> Share

     
     April 2023
232. GERTJE EC, Janelidze S, van Westen D, Cullen N, et al
     Associations Between CSF Markers of Inflammation, White Matter Lesions, and Cognitive Decline in Individuals Without Dementia.
     Neurology. 2023;100:e1812-e1824.
     

     >> Share

     
     
233. KUHN E, Perrotin A, La Joie R, Touron E, et al
     Association of the Informant-Reported Memory Decline With Cognitive and Brain Deterioration Through the Alzheimer Clinical Continuum.
     Neurology. 2023 Apr 21:10.1212/WNL.0000000000207338.
     

     >> Share

     
     
234. INSEL PS, Kumar A, Hansson O, Mattsson-Carlgren N, et al
     Genetic Moderation of the Association of beta-Amyloid With Cognition and MRI in Alzheimer Disease.
     Neurology. 2023 Apr 21:10.1212/WNL.0000000000207305.
     

     >> Share

     
     
235. BRUMM MC, Pierz KA, Lafontant DE, Caspell-Garcia C, et al
     Updated Percentiles for the University of Pennsylvania Smell Identification Test in Adults 50 Years of Age and Older.
     Neurology. 2023;100:e1691-e1701.
     

     >> Share

     
     
236. YANG Z, Wei C, Li X, Yuan J, et al
     Association Between Regular Laxative Use and Incident Dementia in UK Biobank Participants.
     Neurology. 2023;100:e1702-e1711.
     

     >> Share

     
     
237. TIAN J, Raghavan Pillai SK, Reid RI, Przybelski SA, et al
     White Matter Degeneration Pathways Associated With Tau Deposition in Alzheimer Disease.
     Neurology. 2023 Apr 17:10.1212/WNL.0000000000207250.
     

     >> Share

     
     
238. BRODTMANN A, Beversdorf DQ
     The Alzheimer Disconnectome.
     Neurology. 2023 Apr 17:10.1212/WNL.0000000000207303.
     

     >> Share

     
     
239. 
     Incidence of Amyloid-Related Imaging Abnormalities in Patients With Alzheimer Disease Treated With Anti-beta-Amyloid Immunotherapy: A Meta-analysis.
     Neurology. 2023 Apr 4:10.1212/WNL.0000000000207344.
     

     >> Share

     
     
240. WANG Y, Liang J, Fang Y, Yao D, et al
     Burden of Common Neurologic Diseases in Asian Countries, 1990-2019: An Analysis for the Global Burden of Disease Study 2019.
     Neurology. 2023 Apr 4:10.1212/WNL.0000000000207218.
     

     >> Share

     
     March 2023
241. BARKHOF F, Knopman DS
     Brain Shrinkage in Anti-beta-Amyloid Alzheimer Trials: Neurodegeneration or Pseudo-atrophy?
     Neurology. 2023 Mar 27:10.1212/WNL.0000000000207268.
     

     >> Share

     
     
242. ZHANG Y, Liu X, Wiggins KL, Kurniansyah N, et al
     Association of Mitochondrial DNA Copy Number With Brain MRI Markers and Cognitive Function: A Meta-analysis of Community-Based Cohorts.
     Neurology. 2023 Mar 16:10.1212/WNL.0000000000207157.
     

     >> Share

     
     
243. AGARWAL P, Leurgans SE, Agrawal S, Aggarwal N, et al
     Association of Mediterranean-DASH Intervention for Neurodegenerative Delay and Mediterranean Diets With Alzheimer Disease Pathology.
     Neurology. 2023 Mar 8:10.1212/WNL.0000000000207176.
     

     >> Share

     
     
244. KURIHARA M, Komatsu H, Sengoku R, Shibukawa M, et al
     CSF P-Tau181 and Other Biomarkers in Patients With Neuronal Intranuclear Inclusion Disease.
     Neurology. 2023;100:e1009-e1019.
     

     >> Share

     
     
245. CHAPMAN S, Renteria MA, Dworkin JD, Garriga SM, et al
     Association of Subjective Cognitive Decline With Progression to Dementia in a Cognitively Unimpaired Multiracial Community Sample.
     Neurology. 2023;100:e1020-e1027.
     

     >> Share

     
     February 2023
246. TIAN Q, An Y, Kitner-Triolo MH, Davatzikos C, et al
     Associations of Olfaction With Longitudinal Trajectories of Brain Volumes and Neuropsychological Function in Older Adults.
     Neurology. 2023;100:e964-e974.
     

     >> Share

     
     
247. SARTO J, Ruiz-Garcia R, Guillen N, Ramos-Campoy O, et al
     Diagnostic Performance and Clinical Applicability of Blood-Based Biomarkers in a Prospective Memory Clinic Cohort.
     Neurology. 2023;100:e860-e873.
     

     >> Share

     
     
248. FERREIRA D, Przybelski SA, Lesnick TG, Schwarz CG, et al
     Cross-sectional Associations of beta-Amyloid, Tau, and Cerebrovascular Biomarkers With Neurodegeneration in Probable Dementia With Lewy Bodies.
     Neurology. 2023;100:e846-e859.
     

     >> Share

     
     December 2022
249. BARRIO IR, Miki Y, Jaunmuktane ZT, Warner T, et al
     Association Between Orthostatic Hypotension and Dementia in Patients With Parkinson Disease and Multiple System Atrophy.
     Neurology. 2022 Dec 16:10.1212/WNL.0000000000201659.
     

     >> Share

     
     November 2022
250. PROSSER L, MacDougall A, Sudre CH, Manning EN, et al
     Predicting Cognitive Decline in Nondemented Elders Using Baseline Metrics of AD Pathologies, Cerebrovascular Disease, and Neurodegeneration.
     Neurology. 2022 Nov 10. pii: WNL.0000000000201572.
     

     >> Share

     
     October 2022
251. SUCHY-DICEY AM, Oziel K, Sawyer C, Olufadi Y, et al
     Educational and Clinical Associations With Longitudinal Cognitive Function and Brain Imaging in American Indians: The Strong Heart Study.
     Neurology. 2022 Oct 26. pii: WNL.0000000000201261.
     

     >> Share

     
     September 2022
252. ROMERO JR, Pinheiro A, Aparicio HJ, DeCarli CS, et al
     MRI Visible Perivascular Spaces and Risk of Incident Dementia: The Framingham Heart Study.
     Neurology. 2022 Sep 29. pii: WNL.0000000000201293.
     

     >> Share

     
     May 2022
253. TOLLER G, Cobigo Y, Ljubenkov PA, Appleby BS, et al
     Sensitivity of the Social Behavior Observer Checklist to Early Symptoms of Patients With Frontotemporal Dementia.
     Neurology. 2022 May 18. pii: WNL.0000000000200582.
     

     >> Share

     
     

Free Medical Abstracts
Privacy Policy
Sponsors
Share